Introduction: Who Should Undergo Diagnostics

Diagnosing metastatic pancreatic cancer remains one of the greatest challenges in modern medicine. Most people do not experience any specific symptoms in the early stages of the disease, which means that by the time signs appear, the cancer has often already spread to other parts of the body.^[1] This is why understanding when to seek diagnostic evaluation is so important.

Anyone experiencing persistent symptoms such as upper stomach pain that may spread to the back, unexplained weight loss, yellowing of the skin and eyes (a condition called jaundice), loss of appetite, or new-onset diabetes should speak with their doctor immediately and specifically mention pancreatic cancer as a concern.^[2] These symptoms can be vague and may come and go at first, but they often worsen after meals or when lying down.^[7]

People with certain risk factors should be particularly vigilant. If you smoke, have a family history of pancreatic cancer, suffer from chronic inflammation of the pancreas (called pancreatitis), or have recently developed diabetes without obvious reasons, it’s advisable to discuss screening or diagnostic testing with your healthcare provider.^[2] Carrying excess body weight and having certain inherited genetic conditions also increase the likelihood of developing this disease.

Unfortunately, pancreatic cancer often does not show up in routine medical examinations. The pancreas sits deep inside the body, behind the stomach and surrounded by other organs such as the small intestine, liver, and spleen. This location makes early changes difficult to detect without specialized imaging.^[6] Most cases are discovered only at advanced stages, when the cancer has already affected nearby blood vessels or spread to distant organs like the liver or lungs.

Because there is currently no widely accepted screening method for people without symptoms or risk factors, being aware of your body and reporting any changes promptly to your doctor is the best approach.^[4] Healthcare professionals can then decide which diagnostic tests are appropriate based on your individual situation.

Diagnostic Methods

When doctors suspect pancreatic cancer, they use a combination of imaging studies, laboratory tests, and sometimes tissue sampling to confirm the diagnosis and determine how far the disease has spread. Each method provides different information that helps build a complete picture of the patient’s condition.

Imaging Studies

Imaging tests are the primary way to visualize a pancreatic tumor and assess whether the cancer has spread beyond the pancreas. The most commonly used imaging method is a computed tomography scan, or CT scan, which creates detailed cross-sectional images of the body. Doctors often use a CT scan to see if the cancer has reached nearby organs or blood vessels.^[3] However, standard CT scans have limitations when it comes to assessing how well treatment is working to shrink the tumor in the pancreas itself.

Magnetic resonance imaging, or MRI, is another imaging technique that may be used. It provides detailed pictures of soft tissues and can help doctors evaluate the size and location of the tumor. A specialized type of MRI called magnetic resonance cholangiopancreatography (MRCP) can specifically image the pancreas and bile ducts, which is useful when doctors suspect blockages or other complications.

Positron emission tomography, or PET scan, has become increasingly important in diagnosing and monitoring metastatic pancreatic cancer. This test uses a small amount of radioactive material to highlight areas of the body where cells are very active, which often indicates the presence of cancer. PET scans can detect disease spread that may not show up on traditional CT scans, and they are particularly useful for determining whether treatment is effectively controlling the cancer.^[17] When doctors see the response they expect on a PET scan, patients tend to have better outcomes.

Ultrasound examinations use sound waves to create images of internal organs. A pelvic ultrasound or abdominal ultrasound can sometimes help identify abnormalities, though it is less detailed than CT or MRI for pancreatic cancer. A more specialized procedure called endoscopic ultrasound involves passing a thin tube with an ultrasound probe down the throat into the stomach to get very close images of the pancreas. This method can also allow doctors to take tissue samples through a needle biopsy.

Laboratory and Biomarker Testing

Blood tests play an important supporting role in diagnosing metastatic pancreatic cancer. One commonly measured marker is carbohydrate antigen 19-9, or CA 19-9, which is a protein that can be elevated in people with pancreatic cancer.^[1] While CA 19-9 levels alone cannot confirm a diagnosis—since they can also be elevated in other conditions—they can help doctors monitor how well treatment is working over time.

Newer genetic testing methods are being used to analyze blood samples for cancer DNA. This approach, sometimes called liquid biopsy, can help identify patients who might be at higher risk for the cancer returning after treatment.^[17] Some medical centers have pioneered testing not only blood but also fluid from the abdomen during a minimally invasive procedure called laparoscopy to detect traces of cancer that might indicate spread.

Genetic and molecular testing of tumors has become increasingly important. Doctors now routinely test for mutations in genes such as BRCA1 and BRCA2, which are found in about 5% of pancreatic cancer patients.^[9] Knowing whether these mutations are present can influence treatment decisions, as patients with BRCA mutations may benefit from specific types of chemotherapy or newer targeted drugs. Testing for microsatellite instability (MSI) and mismatch repair deficiency (dMMR) is also performed, as a small subset of patients with these features may respond to certain immunotherapy treatments.^[12]

Tissue Biopsy

A biopsy involves taking a small sample of tissue to examine under a microscope. For pancreatic cancer, this is often done using a needle guided by ultrasound or CT imaging. The tissue sample confirms whether cancer cells are present and provides information about the type of cancer and its characteristics. In some cases, doctors may perform a biopsy during an endoscopic procedure or through a surgical approach if other methods are not feasible.

Staging and Classification

Once pancreatic cancer is confirmed, doctors determine its stage, which describes how advanced the disease is. Metastatic pancreatic cancer is classified as stage IV, meaning the cancer has spread to distant parts of the body such as the liver, lungs, or abdominal cavity.^[3] The most common sites of spread are the liver and abdominal wall, though cancer can also reach the lungs, bones, or faraway lymph nodes.^[5]

Understanding the stage helps doctors and patients make informed decisions about treatment options. When the cancer is classified as unresectable, it means that surgery cannot completely remove it because the tumor has spread too far or is too close to vital blood vessels.^[3]

Diagnostics for Clinical Trial Qualification

Clinical trials offer access to new treatments that are not yet widely available and may provide hope for better outcomes. However, to participate in a clinical trial for metastatic pancreatic cancer, patients must meet specific criteria that are verified through diagnostic testing. Understanding these requirements can help patients and their families explore all available options.

Performance Status Assessment

One of the first things researchers evaluate is a patient’s overall health and ability to perform daily activities. This is often measured using a system called the ECOG performance status or similar scales. Patients with good performance status—meaning they can care for themselves and move around without significant limitations—are more likely to be eligible for trials testing intensive combination chemotherapy regimens.^[9] Those with poorer performance status may still qualify for trials of less demanding treatments or supportive care approaches.

Imaging Requirements

Clinical trials typically require recent imaging studies to confirm that the cancer has spread and to measure the size and location of tumors. Most studies ask for a CT scan performed within a few weeks before enrollment. Some trials may also require PET scans or MRI to ensure accurate staging and to establish baseline measurements that will be used to track whether the experimental treatment is working.^[17]

Genetic and Molecular Testing

Many modern clinical trials are designed for patients whose tumors have specific genetic characteristics. For example, trials of PARP inhibitors—a type of targeted drug—enroll only patients with BRCA1 or BRCA2 mutations.^[9] To qualify for these studies, patients must have genetic testing done to confirm the mutation is present. This testing can be performed on a blood sample or on tumor tissue.

Similarly, some immunotherapy trials accept only patients whose tumors show high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).^[12] These features are found in about 1% of pancreatic cancer cases, and testing for them has become more routine as new treatments targeting these abnormalities have been approved.

Laboratory Tests

Before entering a clinical trial, patients undergo blood tests to check the function of vital organs such as the liver and kidneys. Trials often have specific thresholds for blood cell counts, liver enzymes, and kidney function that patients must meet to participate safely. These tests help ensure that patients can tolerate the experimental treatment without experiencing dangerous side effects.

Researchers may also measure tumor markers such as CA 19-9 at the beginning of a trial to establish a baseline. Changes in these markers during treatment can provide early clues about whether the therapy is working.

Previous Treatment History

Some clinical trials are designed for patients who have never received treatment for metastatic disease, while others specifically enroll patients whose cancer has continued to grow despite previous chemotherapy. Documentation of previous treatments, including the types of drugs used and how long they were given, is required for trial enrollment. Patients may need to wait a certain period after completing one treatment before starting a trial of another.

Tissue Samples and Biobanking

Many trials require patients to provide tissue samples from a biopsy, either from the original diagnosis or obtained specifically for the study. These samples are used to perform molecular testing and may be stored in research biobanks for future studies. In some cases, patients may need to undergo an additional biopsy if previous samples are not available or not suitable for the required testing.

Because pancreatic cancer patients are highly encouraged to seek clinical trials at all stages of their disease,^[12] working closely with your healthcare team to complete necessary diagnostic tests early can help open doors to promising new treatments. Ask your doctor whether any clinical trials might be appropriate for your situation and what testing would be needed to determine eligibility.